231 related articles for article (PubMed ID: 27776647)
1. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis.
Adams HJA; Kwee TC
Eur J Radiol; 2016 Nov; 85(11):1963-1970. PubMed ID: 27776647
[TBL] [Abstract][Full Text] [Related]
2. Proportion of false-positive follow-up FDG-PET scans in lymphoma: Systematic review and meta-analysis.
Adams HJA; Kwee TC
Crit Rev Oncol Hematol; 2019 Sep; 141():73-81. PubMed ID: 31252322
[TBL] [Abstract][Full Text] [Related]
3. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Br J Haematol; 2015 Aug; 170(3):356-66. PubMed ID: 25868485
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
Adams HJ; Kwee TC
Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?
Adams HJ; Kwee TC; de Keizer B; Fijnheer R; de Klerk JM; Littooij AS; Nievelstein RA
Ann Oncol; 2014 May; 25(5):921-7. PubMed ID: 24351400
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Hodgkin Lymphoma Patients With a Posttreatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)-Negative Residual Mass: Systematic Review and Meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Pediatr Hematol Oncol; 2015; 32(8):515-24. PubMed ID: 26561044
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.
Adams HJ; Kwee TC
Crit Rev Oncol Hematol; 2016 Oct; 106():55-63. PubMed ID: 27637352
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy.
Adams HJA; Nievelstein RAJ; Kwee TC
Ann Hematol; 2016 Jan; 95(1):1-9. PubMed ID: 26482577
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review.
Adams HJA; Nievelstein RAJ; Kwee TC
Ann Hematol; 2016 Jan; 95(1):11-18. PubMed ID: 26576560
[TBL] [Abstract][Full Text] [Related]
12. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
[TBL] [Abstract][Full Text] [Related]
13. PET imaging for response assessment in lymphoma: potential and limitations.
Schöder H; Moskowitz C
Radiol Clin North Am; 2008 Mar; 46(2):225-41, viii. PubMed ID: 18619378
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review on the Additional Value of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging Follicular Lymphoma.
Adams HJ; Nievelstein RA; Kwee TC
J Comput Assist Tomogr; 2017 Jan; 41(1):98-103. PubMed ID: 27560022
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
Moskowitz CH; Schöder H; Teruya-Feldstein J; Sima C; Iasonos A; Portlock CS; Straus D; Noy A; Palomba ML; O'Connor OA; Horwitz S; Weaver SA; Meikle JL; Filippa DA; Caravelli JF; Hamlin PA; Zelenetz AD
J Clin Oncol; 2010 Apr; 28(11):1896-903. PubMed ID: 20212248
[TBL] [Abstract][Full Text] [Related]
17. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
18. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
19. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma.
Isasi CR; Lu P; Blaufox MD
Cancer; 2005 Sep; 104(5):1066-74. PubMed ID: 16047335
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Burggraaff CN; de Jong A; Hoekstra OS; Hoetjes NJ; Nievelstein RAJ; Jansma EP; Heymans MW; de Vet HCW; Zijlstra JM
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):65-79. PubMed ID: 30141066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]